Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆-Reference-Cited by-同舟云学术

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

Published:2021-05 Issue:5 Volume:32 Page:631-641
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Spigel D.R.,Vicente D.,Ciuleanu T.E.,Gettinger S.,Peters S.,Horn L.,Audigier-Valette C.,Pardo Aranda N.,Juan-Vidal O.,Cheng Y.,Zhang H.,Shi M.,Luft A.,Wolf J.,Antonia S.,Nakagawa K.,Fairchild J.,Baudelet C.,Pandya D.,Doshi P.,Chang H.,Reck M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference35 articles.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 3, 2021.

2. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition);Simon;Chest,2007

3. New advances in the second-line treatment of small cell lung cancer;Hurwitz;Oncologist,2009

4. Relapsed small cell lung cancer: treatment options and latest developments;Asai;Ther Adv Med Oncol,2014

5. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer;von Pawel;J Clin Oncol,2014

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers;BMC Medicine;2024-09-11

3. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer;eClinicalMedicine;2024-09

5. The efficacy and safety of nab-paclitaxel plus anlotinib in small-cell Lung Cancer for third- line therapy;2024-08-11